Inovio Pharmaceuticals (INO) Posts Narrower than Expected Q2 Loss of 18c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Aegis Capital Comments on Inovio (INO) Following Q2 Results; Cash Position Remains 'Solid'
August 11, 2014 11:05 AM EDTAegis Capital affirms Inovio Pharmaceuticals (AMEX: INO) at Buy with a target price of $19 following Q2 results and update released earlier Monday.
Analyst Ram Selvaraju commented, This morning, Inovio reported financial results for the second quarter of 2014. The firm closed the... More
